Opinion: My biggest GLP-1 ethical problem: patients who don’t want to stop
Clinician reflects on ethical dilemmas as some GLP-1 patients seek continued dosing despite unhealthy, excessive weight loss and disordered eating. The piece urges routine evaluation of metabolic markers, eating-disorder history, and consideration of DXA scans before continuing therapy.
Why it mattersGLP-1 super-responders require DXA-informed monitoring to prevent excess muscle or bone loss for clinicians.